NICE to advise firms on how to speed up NHS adoption of their drugsBMJ 2015; 350 doi: https://doi.org/10.1136/bmj.h2813 (Published 22 May 2015) Cite this as: BMJ 2015;350:h2813
All rapid responses
There is a tragic irony in the juxtaposition of two items on the Home page of the BMJ this morning: `Start of cheaper technique for breast cancer is delayed in UK despite adoption elsewhere`  and `NICE to advise firms on how to speed up NHS adoption of their drugs` .
In the course of a discussion on 21 May at a Westminster Forum at a seminar on healthcare research, outlining the decision that the UK National Institute for Health and Care Excellence (NICE) is to set up a new Office of Market Access to advise companies producing new drugs on how to speed up their adoption by the NHS, it is reported  that Leslie Turnberg, chief adviser to the Association of Medical Charities, who chaired the seminar, criticised the speed with which NICE appraised drugs.
The `speed` with which NICE appraise medical devices has also been criticised.  The single dose intraoperative radiotherapy treatment delivered by INTRABEAM – approved and in use elsewhere in the world - will, we are told  not be considered by NICE`s appraisal committee until August 2015 even though their draft guidance recommending INTRABEAM`S use was given in July 2014 following publication of the 5 year follow-up trial results in June 2014. 
This begs the obvious question, should they not put their own house in order?
 Start of cheaper technique for breast cancer is delayed in UK despite adoption elsewhere
BMJ 2015; 350 :h2874 (Published 26 May 2015)
 NICE to advise firms on how to speed up NHS adoption of their drugs
BMJ 2015; 350 :h2813 (Published 22 May 2015)
 Hawkes N. NICE to advise firms on how to speed up NHS adoption of their drugs. BMJ 2015;350:h281
 Thornton H. Rapid response 27th May 2015 to Ref.  http://www.bmj.com/content/350/bmj.h2874/rapid-responses
 Viadya JS, Wenz F, Bulsara M, et al. Risk adapted targeted intraoperative radiotherapy versus whole breast radiotherapy for breast cancer: 5 year results for local control and overall survival from the TARGIT-A randomised trial. Lancet2014;383:603-13.
Competing interests: I was a member of the Data Monitoring Committee for the TARGIT A trial